Phase I studies of vorinostat with ixazomib or pazopanib imply a role of antiangiogenesis-based therapy for TP53 mutant malignancies
Open Access
- 20 February 2020
- journal article
- research article
- Published by Springer Nature in Scientific Reports
- Vol. 10 (1) , 1-9
Abstract
We performed two phase I trials of the histone deacetylase inhibitor vorinostat combined with either the vascular endothelial growth factor inhibitor pazopanib (NCT01339871) or the proteasome inhibitor ixazomib (NCT02042989) in patients with metastatic TP53 mutant solid tumors. Both trials followed a 3 + 3 dose-escalation design allowing for a dose expansion cohort of up to 14 additional patients with a specific tumor type. Patients had to have a confirmed TP53 mutation to be enrolled in NCT02042989. Among patients enrolled in NCT01339871, TP53 mutation status was determined for those for whom tumor specimens were available. The results of NCT01339871 were reported previously. Common treatment-related adverse events in NCT02042989 included anemia, thrombocytopenia, fatigue, nausea, vomiting, and diarrhea. Compared with patients with metastatic TP53 hotspot mutant solid tumors who were treated with ixazomib and vorinostat (n = 59), those who were treated with pazopanib and vorinostat (n = 11) had a significantly higher rate of clinical benefit, defined as stable disease lasting ≥6 months or an objective response (3.4% vs. 45%; p < 0.001), a significantly longer median progression-free survival duration (1.7 months [95% confidence interval (CI), 1.1–2.3] vs. 3.5 months [95% CI, 1.7–5.2]; p = 0.002), and a longer median overall survival duration (7.3 months [95% CI, 4.8–9.8] vs. 12.7 months [95% CI, 7.1–18.3]; p = 0.24). Our two phase I trials provide preliminary evidence supporting the use of antiangiogenisis-based therapy in patients with metastatic TP53 mutant solid tumors, especially in those with metastatic sarcoma or metastatic colorectal cancer.Keywords
Funding Information
- Takeda Pharmaceutical Company Limited | Takeda Oncology
- Takeda Pharmaceutical Company
- U.S. Department of Health & Human Services | NIH | National Cancer Institute (P30CA016672)
This publication has 50 references indexed in Scilit:
- Potential tumorigenic programs associated with TP53 mutation status reveal role of VEGF pathwayBritish Journal of Cancer, 2012
- SAHA shows preferential cytotoxicity in mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 chaperone axisCell Death & Differentiation, 2011
- P53-induced microRNA-107 inhibits HIF-1 and tumor angiogenesisProceedings of the National Academy of Sciences, 2010
- HIF-1: upstream and downstream of cancer metabolismCurrent Opinion in Genetics & Development, 2010
- Targeting tumor angiogenesis with histone deacetylase inhibitorsCancer Letters, 2009
- Cytoplasmic functions of the tumour suppressor p53Nature, 2009
- Antiangiogenic Therapy Elicits Malignant Progression of Tumors to Increased Local Invasion and Distant MetastasisCancer Cell, 2009
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Hypoxia-Inducible Factors, Stem Cells, and CancerCell, 2007
- Cancer genes and the pathways they controlNature Medicine, 2004